alzheimer's disease

Online study partner-reported cognitive decline in the Brain Health Registry.

Authors: Camacho MR, Finley S, Flenniken D, Fockler J, Insel PS, Mackin RS, Maruff P, Nosheny RL, Truran D, Ulbricht A, Weiner MW, Yaffe K

Journal: Alzheimer's & Dementia

Introduction: Methods for efficiently identifying cognitive decline and Alzheimer’s disease (AD) are a critical unmet need. The goal of this work was to validate novel online study partner (SP)-reported outcomes to identify cognitive decline in older […]

Patient perspectives of the experience of a computerized cognitive assessment in a clinical setting.

Authors: Feng TL, Hayden S, Lai JA, Robillard JM, Wu JM

Journal: Alzheimer's and Dementia

Introduction: Computerized assessments are becoming widely accepted in the clinical setting and as a potential outcome measure in clinical trials. To gain patient perspectives of this experience, the aim of the present study was to investigate […]

The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies.

Authors: Camacho M, Finley S, Flenniken D, Fockler J, Insel P, Mackin RS, Nosheny R, Truran-Sacrey D, Ulbricht A, Veitch D, Weiner MW

Journal: Alzheimer's and Dementia

INTRODUCTION: Recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies and clinical trials limit the development of new treatments. Widespread Internet use allows data capture from participants in an unsupervised setting. The Brain Health Registry, […]

Influence of amyloid and apolipoprotein E on cognitive performance in a late middle-aged cohort.

Authors: Christianson TJ, Hagen CE, Jack CR Jr, Knopman DS, Kremers WK, Lowe VJ, Machulda MM, Mielke MM, Petersen RC, Roberts RO, Vemuri P

Journal: Alzheimer's & Dementia

INTRODUCTION: Few studies have examined the effects of amyloid and apolipoprotein E (APOE) genotype on cognition among middle-aged individuals. METHODS: We included 464 cognitively normal, test-na├»ve, participants with Pittsburgh compound B positron emission tomography amyloid imaging, […]

A 24-week Study to Evaluate the Effect of Rilapladib on Cognition and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Authors: Andrew Lockhart, Arseniy Lavrov, Carly Barnett, Gareth Maher-Edwards, Jeni De'Ath

Journal: Alzheimer's & Dementia

Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer’s disease (AD). Methods: One hundred twenty-four subjects with possible mild AD and with neuroimaging […]

1 2 3

Back to Publications